Histopathological and some biochemical effects of platinum drug on the liver and kidney of pregnant mice mus musculus and their embryos

Abstract EN

The current study was done to investigate the effects of two doses 3and 6 mg/kg B.

w.

of the Platinum drug on the structure of the liver and kidney of pregnant mice, and embryos in addition to the weight of the mothers, embryos, maternal liver and kidneys, as well as some biochemical parameters, were established.

For this study, thirty pregnant mice were used, divided into three groups (10 mice/group) as follows; group I (control group); animals were injected intraperitoneally (IP) with distilled water on the days 7th, 12th, and 17th of gestation.

The other both groups II, and III were injected intraperitoneally (IP) with the selected doses above of the Platinum at the days 7th, 12th, and 17th of gestation, respectively.

Microscopically, maternal and fetal' liver sections of group II revealed vacuolation, swelling, apoptosis, infiltration of inflammatory cells, congestion, degeneration, and presence of the extramedullary hematopoietic cells, respectively.

Previous lesions were increased in group III.

Maternal and, fetal kidney sections of group II revealed degeneration, expansion of Bowman's space, inflammatory cells infiltration into interstitial tissue, and blood capillaries congestion.

However, the previous lesions showed more severity in group III.

The drug caused a reduction in the body weight of the mothers, selected organs, and embryos.

Biochemical assessment of the maternal serum AST, ALT, and ALP levels showed an increase in both experimental groups II and III, but to varying degrees.

Moreover, both groups II and III showed an increase in the levels of the maternal BUN and, urea.

Whist, group III showed a significant increase of the creatinine compared to the control group.

In conclusion, using anticancer drugs during pregnancy will harm both mothers and fetal organs.

The risk of these medications represents their ability to cross the placenta and enters the fetal body.

Therefore, the drug may affect the formation of the fetal organs.

The drug also alters the regulatory antioxidant mechanism in the maternal body during the treatment duration.

The drug should be used under medical follow up.